✦ LIBER ✦

Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective

✍ Scribed by VanHoff, David; Hesser, Tanya; Kelly, Katherine; Freyer, David; Stork, Susan; Sung, Lillian

Book ID: 121567263
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 263 KB
Volume: 13
Category: Article
ISSN: 1471-2288
DOI: 10.1186/1471-2288-13-154

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Barriers and facilitators to enrollment

Barriers and facilitators to enrollment in cancer clinical trials : Qualitative study of the perspectives of clinical research associates

✍ Eva Grunfeld; Louise Zitzelsberger; Marjorie Coristine; Faye Aspelund 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract ## BACKGROUND The literature continues to report low rates of accrual to cancer clinical trials. Previous studies have examined principally physician‐related or patient‐related barriers. Clinical research associates (CRAs) have a unique perspective on enrollment that has been explored

Cancer clinical trial recruitment : The

Cancer clinical trial recruitment : The emerging role and perspectives of clinical research associates and data managers

✍ Martin Tattersall 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 1 views

Clinical Research Associates have assumed an expanding role in the conduct and design of clinical trial protocols. The perspectives of these health professionals are presented in the referenced articles, and implications for clinical trials are discussed. See also pages 1577–83 and 1584–91.

The TREAT-NMD care and trial site regist

The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

✍ Rodger, Sunil; Lochmüller, Hanns; Tassoni, Adrian; Gramsch, Kathrin; König, Kirs 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 640 KB

A feasibility study to inform the design

A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study

✍ Joanna D Smith,Jessica Baillie,Trevor Baglin,Gareth O Griffiths… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 614 KB

786 A randomized, double blind, placebo

786 A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 antigen specific cancer immunotherapy in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy: An initial report of the EAU Research Foundation randomized phase II clinical trial ‘Magnolia’

✍ Mulders, P.F.A.; Colombel, M.; Heidenreich, A.; Martínez-Piñeiro, L.; Babjuk, M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB